Figure 1.

Evolution over time of the depressive symptoms, as assessed on the Montgomery Asberg Depression Rating Scale (MADRS). The scores of 2 randomized patients were not included as they dropped out due to side effects. Medication regimens were titrated weekly, but they could remain on the same dose level for an additional 1 or 2 weeks, but all patients reached level 4 for at least for 1 week after 6 weeks. Atomoxetine levels were 25, 43, 65, and 80 mg/d; venlafaxine levels were 75, 150, 225, and 375 mg/d; paroxetine levels were: 20, 30, 40, and 50 mg/d. *P < .05 denotes significant improvement between baseline scores and levels 2–4 in each group.